35.50
—
Close of 4 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sunrest Lifescience
Its shares trade on NSE under the ticker SUNREST.NS. It has been listed since 20 November 2023. In the fiscal year to 31 March 2025, it reported revenue of ₹334.1m and net income of ₹20.1m. At that date it held total assets of ₹586.5m and shareholders' equity of ₹163.1m.
Sunrest Lifescience Ltd is a IN-based company operating in industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-11-20. Sunrest Lifescience Limited is an India-based pharmaceutical company. The firm is engaged in the marketing of over the counter (OTC) generic pharmaceutical products manufactured by third party manufacturers in the domestic market. The company deals in capsules, tablets, syrup, ointment, gel, mouth wash, solution, suspension, dry powders and toothpaste. The Company’s product portfolio comprises a range of drugs like Anti-Bacterial, Anti Diarrheal, Antifungal, Anti Malerial, Anti Diabetic, Dental Cure, Anti Protozol, Anti Histamine, Anti-Hypertensive drugs, Cosmetic, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical and Anti-inflammatory. The firm operates in different States of India, such as Maharashtra, Gujarat, Madhya Pradesh, Orissa and Rajasthan. The products of the Company are sold to stockists and in turn it is available at chemist shops, dispensaries, and hospitals, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 20 Nov 2023
- Website
- sunrestlifescience.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sunrest Lifescience Ltd operates in the pharmaceutical industry with a strong focus on OTC generic products in India.
- The company has a diverse product portfolio including Anti-Bacterial, Anti Diarrheal, and Anti-Hypertensive drugs.
- Sunrest Lifescience Ltd serves multiple states including Maharashtra, Gujarat, and Rajasthan with its pharmaceutical products.
Weaknesses
- Sunrest Lifescience Ltd relies on third-party manufacturers for its OTC generic pharmaceutical products.
- The company's product range includes only basic pharmaceutical categories without advanced specialty drugs.
- Sunrest Lifescience Ltd has limited market presence outside of India's domestic market.
Opportunities
- Sunrest Lifescience Ltd can expand its product line to include specialty pharmaceuticals in the Indian market.
- The growing Indian pharmaceutical market offers potential for increased sales of OTC generic products.
- Sunrest Lifescience Ltd can target new states like Karnataka and Telangana for market expansion.
Threats
- Sunrest Lifescience Ltd faces competition from established pharmaceutical companies in the Indian market.
- The Indian pharmaceutical industry is subject to regulatory changes that could affect product approvals.
- Sunrest Lifescience Ltd must comply with strict quality standards for OTC generic pharmaceutical products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.